^
Association details:
| Biomarker: | EGFR exon 21 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients
Published date:
12/27/2022
Excerpt:
In the subgroup with women, < 65 years, ECOG (Eastern Cooperative Oncology Group) 0–1, nonsmoker, EGFR 21 mutation, and positive EGFR T790M mutation, PFS was significantly longer in the Chemo + IO group….Pembrolizumab combined with chemotherapy may improve PFS and survival compared to platinum-based chemotherapy alone in pre-treated EGFR-mutant NSCLC patients after EGFR-TKI therapy discontinuation.
Secondary therapy:
Chemotherapy
DOI:
10.1016/j.cllc.2022.12.003
